Concentrated heart-activating pill and preparation method thereof

Abstract

The invention relates to the technical field of traditional Chinese medicines, in particular to a concentrated heart-activating pill and a preparation method thereof. The preparation method comprises the following steps: weighing raw materials including lucid ganoderma, artificial musk, bear gall, calculus bovis, pearl, ginseng, venenum bufonis, radix aconiti carmichaeli, borneol, safflower and starch; ganoderma lucidum, ginseng, venenum bufonis, radix aconiti carmichaeli and safflower are smashed to obtain powder, water is added for boiling, heat preservation and stirring are conducted, and a first intermediate product is obtained; adding fig protease and ginger protease into the intermediate product I, and performing enzyme deactivation to obtain an intermediate product II; sterilizing the intermediate product II, adding a carbon source, a nitrogen source and zymophyte, fermenting, sterilizing and filtering to obtain an intermediate product III filtrate; adding artificial musk, bear gall, calculus bovis, pearl, borneol and starch into the intermediate product III, stirring, concentrating under reduced pressure, kneading pills, and drying to obtain the concentrated heart-activating pills. The concentrated active pill prepared by the invention has an excellent blood fat reducing effect, and has the effects of remarkably reducing the TC, TG and LDL-C contents in serum and effectively increasing the HDL-C content.

Description

Technical Field

[0001] The invention relates to the technical field of traditional Chinese medicines, and in particular to a concentrated heart-activating pill and a preparation method thereof. Background Art

[0002] Huoxin Pills are made up of Ganoderma lucidum, artificial musk, bear bile, in vitro cultured bezoar, pearl, ginseng, toad venom, aconite, borneol and safflower. Ganoderma lucidum, safflower and ginseng are the main drugs for invigorating qi and promoting blood circulation. Bezoar and borneol are aromatic and can open the mind, promote qi and dissipate blood stasis; musk and toad venom are pungent, dispersing, warming and unblocking, and are aromatic and can open the mind and relieve numbness, and are the assistant drugs. Bear bile and pearl can calm the mind and stabilize the spirit; aconite is pungent, warm and dry, can replenish fire and promote yang, dispel cold and relieve numbness, and can not only help invigorate qi and promote yang, but also prevent the coldness of bezoar, pearl and bear bile, and are the adjuvant drugs. The combination of these drugs can play the role of invigorating qi and promoting blood circulation, aromatic and opening the mind, relieving numbness and relieving pain. In clinical practice, Huoxin Pills are used to treat chest tightness, precordial pain, palpitations, shortness of breath, fatigue, thin pulse and purple tongue caused by insufficient heart qi, stasis of heart blood, obstruction of heart meridians and failure of chest yang to be released.

[0003] In addition to its ability to treat cardiovascular diseases, Huoxin Pills need to further develop its processing technology to obtain concentrated pills and give them excellent effects in preventing or treating hyperlipidemia, thereby expanding its application. Summary of the invention

[0004] The present invention aims at the above technical problems and proposes a technical solution of the present invention, which includes a concentrated heart-activating pill and a preparation method thereof.

[0005] The present invention provides a method for preparing concentrated heart-activating pills, comprising the following steps: Step 1: weigh the raw materials: ganoderma lucidum, artificial musk, bear gall, bezoar, pearl, ginseng, toad venom, aconite root, borneol, safflower and starch; Step 2: Ganoderma lucidum, ginseng, toad venom, aconite root and safflower are crushed to obtain powder, and water is added to boil and then stirred to obtain intermediate product 1; Step 3: adding ficin and ginger protease to the intermediate product 1, performing enzymolysis and inactivating the enzymes to obtain the intermediate product 2; Step 4: sterilize the intermediate product II, add a carbon source, a nitrogen source and fermentation bacteria, ferment, sterilize, and filter to obtain an intermediate product III filtrate; Step 5: Add artificial musk, bear bile, bezoar, pearl, borneol and starch to the intermediate product three, stir, concentrate under reduced pressure, make pills, and dry to obtain the concentrated heart-activating pills.

[0006] Preferably, in step 1, the raw materials are weighed according to mass: 20-40 parts of Ganoderma lucidum, 0.2-0.5 parts of artificial musk, 0.5-2 parts of bear bile, 0.2-0.5 parts of bezoar, 0.2-0.4 parts of pearl, 20-30 parts of ginseng, 2-5 parts of toad venom, 8-15 parts of aconite, 0.2-0.5 parts of borneol, 2-6 parts of safflower and 3-6 parts of starch.

[0007] Preferably, in step 2, the mass ratio of powder to water is 1:15-40; and the heat preservation and stirring conditions are: heat preservation and stirring at 70-82° C. for 2-6 hours.

[0008] Preferably, in step 3, the amounts of ficin and ginger protease added to the intermediate product 1 are 220-400u / g and 250-500u / g respectively; and the enzymatic hydrolysis conditions are: enzymatic hydrolysis at 40-60°C and stirring for 2-5 hours.

[0009] Preferably, in step 4, the carbon source includes glucose, which is added to product two in an amount of 1-4wt%; the nitrogen source includes potassium dihydrogen phosphate, which is added to product two in an amount of 0.02-0.065wt%.

[0010] Preferably, in step 4, the fermentation bacteria are composed of live bacteria of Lactobacillus paracasei CICC 6235 and Bacillus subtilis CICC10262 in a quantitative ratio of 1:1.2-2.5, and the total inoculation number of live bacteria of the fermentation bacteria in the intermediate product 2 is 1.1×10 10 -3.7×10 10 cfu / g.

[0011] Preferably, in step 4, the fermentation condition is stirring at 30-38° C. for 100-200 hours.

[0012] Preferably, in step 5, the vacuum concentration temperature is 50-55° C., and the vacuum concentration is performed to a water content of 10-15 wt %.

[0013] Preferably, in step 5, vacuum drying is used for drying, and the drying temperature is 60-70°C.

[0014] Preferably, in step 5, drying is performed until the water content is less than 5 wt %.

[0015] The present invention also provides concentrated heart-activating pills prepared according to the preparation method.

[0016] Beneficial effects of the present invention: The preparation method comprises: weighing raw materials such as ganoderma lucidum, artificial musk, bear gall, bezoar, pearl, ginseng, toad venom, aconite, borneol, safflower and starch; crushing ganoderma lucidum, ginseng, toad venom, aconite and safflower to obtain powder, adding water to boil and then stirring to obtain intermediate product one; adding ficin and ginger protease to intermediate product one, inactivating enzymes to obtain intermediate product two; sterilizing intermediate product two, adding carbon source, nitrogen source and fermentation bacteria, fermenting, sterilizing, filtering, obtaining intermediate product three filtrate; adding artificial musk, bear gall, bezoar, pearl, borneol and starch to intermediate product three, stirring, concentrating under reduced pressure, kneading pills, drying, and obtaining the concentrated active pills. The concentrated active pills prepared by the present invention have excellent blood lipid-lowering effect, can significantly reduce the content of TC, TG and LDL-C in serum and effectively improve the content of HDL-C.

[0017] The invention adopts enzymolysis and fermentation processes, which can effectively improve the efficacy of the pills and increase their blood lipid lowering effect.

[0018] During enzymolysis, the present invention uses a combination of ficin and ginger protease, which can produce a compound effect, effectively reduce the TC, TG and LDL-C contents in serum and increase the HDL-C content, giving the active pills excellent lipid-lowering effect.

[0019] In the fermentation process of the present invention, Lactobacillus paracasei CICC 6235 and Bacillus subtilis CICC 10262 are used for joint fermentation, and the two have a synergistic effect in promoting the effect of lowering blood lipids. The joint fermentation of the two can significantly reduce the content of TC, TG and LDL-C and increase the content of HDL-C. In the fermentation process, when the live bacteria of Lactobacillus paracasei CICC 6235 and Bacillus subtilis CICC 10262 are selected in a quantity ratio within the range of 1:1.2-2.5, the prepared active pills have better effect.

[0020] The preparation method of the invention is simple, and the prepared active pills have excellent effects and good application prospects. DETAILED DESCRIPTION

[0021] The present invention will be described below in conjunction with specific embodiments, and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific embodiments are used to illustrate the present invention, rather than to limit the present invention.

[0022] Starch: corn starch with mesh less than 100. Lactobacillus paracasei CICC 6235 and Bacillus subtilis CICC 10262 were purchased from China Industrial Microbiological Culture Collection Center. Bezoar: in vitro cultured bezoar was purchased from Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd.

[0023] Preparation of Huoxin Pills: Pill 1: Step 1: weigh the following raw materials by mass: 30 parts of Ganoderma lucidum, 0.4 parts of artificial musk, 1 part of bear gall, 0.35 parts of bezoar, 0.3 parts of pearl, 25 parts of ginseng, 4 parts of toad venom, 12 parts of aconite root, 0.4 parts of borneol, 5 parts of safflower and 5 parts of starch; Step 2: Ganoderma lucidum, ginseng, toad venom, aconite root and safflower are crushed to obtain powder, and water 32 times the weight of the powder is added, and the mixture is boiled and kept at 78°C and stirred at 60 rpm for 4.5 hours to obtain an intermediate product 1; Step 3: add 300u / g of ficin and 400u / g of ginger to the intermediate product 1, perform enzymolysis at 55°C and stir at 60rpm for 3.8 hours, then inactivate the enzyme to obtain the intermediate product 2; Step 4: sterilize the intermediate product 2, add 3.2% of the carbon source glucose, 0.05% of the nitrogen source potassium dihydrogen phosphate and fermentation bacteria compared to the mass of the intermediate product 2, control the fermentation temperature to 37°C and stir at 60 rpm for 170 hours, then sterilize and filter to obtain the intermediate product 3 filtrate; The fermentation bacteria are Lactobacillus casei CICC 6235 and Bacillus subtilis CICC 10262 in a ratio of 1:2. The total inoculation number of live fermentation bacteria in the intermediate product 2 is 2.70×10 10 cfu / g; Step 5: Add artificial musk, bear bile, bezoar, pearl, borneol and starch to the intermediate product three, stir at 80rpm for 0.5 hour, then concentrate under reduced pressure at 55°C to a water content of 14wt%, pinch into pills, and vacuum dry at 68°C to a water content of 4.27wt% to obtain the concentrated active heart pills.

[0024] Pill 2: Step 1: weigh the following raw materials by mass: 20 parts of Ganoderma lucidum, 0.2 parts of artificial musk, 1.5 parts of bear gall, 0.2 parts of bezoar, 0.4 parts of pearl, 30 parts of ginseng, 5 parts of toad venom, 15 parts of aconite root, 0.2 parts of borneol, 2 parts of safflower and 5 parts of starch; Step 2: Ganoderma lucidum, ginseng, toad venom, aconite root and safflower are crushed to obtain powder, and water 35 times the weight of the powder is added, and the mixture is boiled, kept warm at 80°C, and stirred at 60 rpm for 4 hours to obtain an intermediate product 1; Step 3: add 400u / g of ficin and 320u / g of ginger to the intermediate product 1, perform enzymolysis at 52°C and stir at 60rpm for 3.2 hours, then inactivate the enzyme to obtain the intermediate product 2; Step 4: sterilize the intermediate product 2, add 3.15% of the carbon source glucose, 0.06% of the nitrogen source potassium dihydrogen phosphate and fermentation bacteria compared to the mass of the intermediate product 2, control the fermentation temperature to 35°C and stir at 60rpm for 120 hours, then sterilize and filter to obtain the filtrate of the intermediate product 3; The fermentation bacteria are composed of live bacteria of Lactobacillus paracasei CICC 6235 and Bacillus subtilis CICC 10262 in a ratio of 1:1.5, and the total inoculation number of live bacteria of the fermentation bacteria in the intermediate product 2 is 2.85×10 10 cfu / g; Step 5: Add artificial musk, bear bile, bezoar, pearl, borneol and starch to the intermediate product three, stir at 80rpm for 0.5 hour, then concentrate under reduced pressure at 55°C to a water content of 13.8wt%, pinch into pills, and vacuum dry at 68°C to a water content of 4.15wt% to obtain the concentrated active heart pills.

[0025] Pill 3: Step 1: weigh the following raw materials by mass: 30 parts of Ganoderma lucidum, 0.4 parts of artificial musk, 1 part of bear gall, 0.35 parts of bezoar, 0.3 parts of pearl, 25 parts of ginseng, 4 parts of toad venom, 12 parts of aconite root, 0.4 parts of borneol, 5 parts of safflower and 5 parts of starch; Step 2: Ganoderma lucidum, ginseng, toad venom, aconite root and safflower are crushed to obtain powder, and water 32 times the weight of the powder is added, and the mixture is boiled and kept at 78°C and stirred at 60 rpm for 4.5 hours to obtain an intermediate product 1; Step 3: sterilize the intermediate product 1, add 3.2% of the mass of the carbon source glucose, 0.05% of the nitrogen source potassium dihydrogen phosphate and fermentation bacteria compared to the mass of the intermediate product 1, control the fermentation temperature to 37°C and stir at 60 rpm for 170 hours, then sterilize and filter to obtain the intermediate product 2 filtrate; The fermentation bacteria are composed of live bacteria of Lactobacillus paracasei CICC 6235 and Bacillus subtilis CICC 10262 in a ratio of 1:2, and the total inoculation number of live bacteria of the fermentation bacteria in the intermediate product 1 is 2.70×10 10 cfu / g; Step 5: Add artificial musk, bear bile, bezoar, pearl, borneol and starch to the intermediate product 2, stir at 80rpm for 0.5 hour, then concentrate under reduced pressure at 55°C to a water content of 14wt%, knead into pills, and vacuum dry at 68°C to a water content of 4.27wt% to obtain the concentrated active heart pills.

[0026] Pill 4: Step 1: weigh the following raw materials by mass: 30 parts of Ganoderma lucidum, 0.4 parts of artificial musk, 1 part of bear gall, 0.35 parts of bezoar, 0.3 parts of pearl, 25 parts of ginseng, 4 parts of toad venom, 12 parts of aconite root, 0.4 parts of borneol, 5 parts of safflower and 5 parts of starch; Step 2: Ganoderma lucidum, ginseng, toad venom, aconite root and safflower are crushed to obtain powder, and water 32 times the weight of the powder is added, and the mixture is boiled and kept at 78°C and stirred at 60 rpm for 4.5 hours to obtain an intermediate product 1; Step 3: add 700u / g of ficin to the intermediate product 1, perform enzymolysis at 55°C and stir at 60rpm for 3.8 hours, then inactivate the enzyme to obtain the intermediate product 2; Step 4: sterilize the intermediate product 2, add 3.2% of the carbon source glucose, 0.05% of the nitrogen source potassium dihydrogen phosphate and fermentation bacteria compared to the mass of the intermediate product 2, control the fermentation temperature to 37°C and stir at 60 rpm for 170 hours, then sterilize and filter to obtain the intermediate product 3 filtrate; The fermentation bacteria are Lactobacillus casei CICC 6235 and Bacillus subtilis CICC 10262 in a ratio of 1:2. The total inoculation number of live fermentation bacteria in the intermediate product 2 is 2.70×10 10 cfu / g; Step 5: Add artificial musk, bear bile, bezoar, pearl, borneol and starch to the intermediate product three, stir at 80rpm for 0.5 hour, then concentrate under reduced pressure at 55°C to a water content of 14wt%, pinch into pills, and vacuum dry at 68°C to a water content of 4.27wt% to obtain the concentrated active heart pills.

[0027] Pill 5: Step 1: weigh the following raw materials by mass: 30 parts of Ganoderma lucidum, 0.4 parts of artificial musk, 1 part of bear gall, 0.35 parts of bezoar, 0.3 parts of pearl, 25 parts of ginseng, 4 parts of toad venom, 12 parts of aconite root, 0.4 parts of borneol, 5 parts of safflower and 5 parts of starch; Step 2: Ganoderma lucidum, ginseng, toad venom, aconite root and safflower are crushed to obtain powder, and water 32 times the weight of the powder is added, and the mixture is boiled and kept at 78°C and stirred at 60 rpm for 4.5 hours to obtain an intermediate product 1; Step 3: adding 700 u / g of ginger protease to the intermediate product 1, performing enzymolysis at 55° C. and stirring at 60 rpm for 3.8 hours, and then inactivating the enzyme to obtain the intermediate product 2; Step 4: sterilize the intermediate product 2, add 3.2% of the carbon source glucose, 0.05% of the nitrogen source potassium dihydrogen phosphate and fermentation bacteria compared to the mass of the intermediate product 2, control the fermentation temperature to 37°C and stir at 60 rpm for 170 hours, then sterilize and filter to obtain the intermediate product 3 filtrate; The fermentation bacteria are Lactobacillus casei CICC 6235 and Bacillus subtilis CICC 10262 in a ratio of 1:2. The total inoculation number of live fermentation bacteria in the intermediate product 2 is 2.70×10 10 cfu / g; Step 5: Add artificial musk, bear bile, bezoar, pearl, borneol and starch to the intermediate product three, stir at 80rpm for 0.5 hour, then concentrate under reduced pressure at 55°C to a water content of 14wt%, pinch into pills, and vacuum dry at 68°C to a water content of 4.27wt% to obtain the concentrated active heart pills.

[0028] Pill 6: Step 1: weigh the following raw materials by mass: 30 parts of Ganoderma lucidum, 0.4 parts of artificial musk, 1 part of bear gall, 0.35 parts of bezoar, 0.3 parts of pearl, 25 parts of ginseng, 4 parts of toad venom, 12 parts of aconite root, 0.4 parts of borneol, 5 parts of safflower and 5 parts of starch; Step 2: Ganoderma lucidum, ginseng, toad venom, aconite root and safflower are crushed to obtain powder, and water 32 times the weight of the powder is added, and the mixture is boiled and kept at 78°C and stirred at 60 rpm for 4.5 hours to obtain an intermediate product 1; Step 3: add 300u / g of intermediate product 1 ficin and 400u / g of intermediate product 1 ginger protease to the intermediate product 1, perform enzymolysis at 55°C and stir at 60rpm for 3.8 hours, then inactivate the enzyme and filter to obtain the intermediate product 2 filtrate; Step 4: Add artificial musk, bear bile, bezoar, pearl, borneol and starch to the intermediate product 2, stir at 80rpm for 0.5 hour, then concentrate under reduced pressure at 55°C to a water content of 14wt%, pinch into pills, and vacuum dry at 68°C to a water content of 4.27wt% to obtain the concentrated active heart pills.

[0029] Pill 7: Step 1: weigh the following raw materials by mass: 30 parts of Ganoderma lucidum, 0.4 parts of artificial musk, 1 part of bear gall, 0.35 parts of bezoar, 0.3 parts of pearl, 25 parts of ginseng, 4 parts of toad venom, 12 parts of aconite root, 0.4 parts of borneol, 5 parts of safflower and 5 parts of starch; Step 2: Ganoderma lucidum, ginseng, toad venom, aconite root and safflower are crushed to obtain powder, and water 32 times the weight of the powder is added, and the mixture is boiled and kept at 78°C and stirred at 60 rpm for 4.5 hours to obtain an intermediate product 1; Step 3: add 300u / g of ficin and 400u / g of ginger to the intermediate product 1, perform enzymolysis at 55°C and stir at 60rpm for 3.8 hours, then inactivate the enzyme to obtain the intermediate product 2; Step 4: sterilize the intermediate product 2, add 3.2% of the carbon source glucose, 0.05% of the nitrogen source potassium dihydrogen phosphate and fermentation bacteria compared to the mass of the intermediate product 2, control the fermentation temperature to 37°C and stir at 60 rpm for 170 hours, then sterilize and filter to obtain the intermediate product 3 filtrate; Among them, the fermentation bacteria was Lactobacillus casei CICC 6235, and the total number of live inoculated bacteria in the intermediate product 2 was 2.70×10 10cfu / g; Step 5: Add artificial musk, bear bile, bezoar, pearl, borneol and starch to the intermediate product three, stir at 80rpm for 0.5 hour, then concentrate under reduced pressure at 55°C to a water content of 14wt%, pinch into pills, and vacuum dry at 68°C to a water content of 4.27wt% to obtain the concentrated active heart pills.

[0030] Pill 8: Step 1: weigh the following raw materials by mass: 30 parts of Ganoderma lucidum, 0.4 parts of artificial musk, 1 part of bear gall, 0.35 parts of bezoar, 0.3 parts of pearl, 25 parts of ginseng, 4 parts of toad venom, 12 parts of aconite root, 0.4 parts of borneol, 5 parts of safflower and 5 parts of starch; Step 2: Ganoderma lucidum, ginseng, toad venom, aconite root and safflower are crushed to obtain powder, and water 32 times the weight of the powder is added, and the mixture is boiled and kept at 78°C and stirred at 60 rpm for 4.5 hours to obtain an intermediate product 1; Step 3: add 300u / g of ficin and 400u / g of ginger to the intermediate product 1, perform enzymolysis at 55°C and stir at 60rpm for 3.8 hours, then inactivate the enzyme to obtain the intermediate product 2; Step 4: sterilize the intermediate product 2, add 3.2% of the carbon source glucose, 0.05% of the nitrogen source potassium dihydrogen phosphate and fermentation bacteria compared to the mass of the intermediate product 2, control the fermentation temperature to 37°C and stir at 60 rpm for 170 hours, then sterilize and filter to obtain the intermediate product 3 filtrate; Among them, the fermentation bacteria is Bacillus subtilis CICC 10262, and the total number of live bacteria inoculated in the intermediate product 2 is 2.70×10 10 cfu / g; Step 5: Add artificial musk, bear bile, bezoar, pearl, borneol and starch to the intermediate product three, stir at 80rpm for 0.5 hour, then concentrate under reduced pressure at 55°C to a water content of 14wt%, pinch into pills, and vacuum dry at 68°C to a water content of 4.27wt% to obtain the concentrated active heart pills.

[0031] Pill 9: Step 1: weigh the following raw materials by mass: 30 parts of Ganoderma lucidum, 0.4 parts of artificial musk, 1 part of bear gall, 0.35 parts of bezoar, 0.3 parts of pearl, 25 parts of ginseng, 4 parts of toad venom, 12 parts of aconite root, 0.4 parts of borneol, 5 parts of safflower and 5 parts of starch; Step 2: Ganoderma lucidum, ginseng, toad venom, aconite root and safflower are crushed to obtain powder, and water 32 times the weight of the powder is added, and the mixture is boiled and kept at 78°C and stirred at 60 rpm for 4.5 hours to obtain an intermediate product 1; Step 3: add 300u / g of ficin and 400u / g of ginger to the intermediate product 1, perform enzymolysis at 55°C and stir at 60rpm for 3.8 hours, then inactivate the enzyme to obtain the intermediate product 2; Step 4: sterilize the intermediate product 2, add 3.2% of the carbon source glucose, 0.05% of the nitrogen source potassium dihydrogen phosphate and fermentation bacteria compared to the mass of the intermediate product 2, control the fermentation temperature to 37°C and stir at 60 rpm for 170 hours, then sterilize and filter to obtain the intermediate product 3 filtrate; The fermentation bacteria are composed of live bacteria of Lactobacillus paracasei CICC 6235 and Bacillus subtilis CICC 10262 in a ratio of 1:0.2, and the total inoculation number of live bacteria of the fermentation bacteria in the intermediate product 2 is 2.70×10 10 cfu / g; Step 5: Add artificial musk, bear bile, bezoar, pearl, borneol and starch to the intermediate product three, stir at 80rpm for 0.5 hour, then concentrate under reduced pressure at 55°C to a water content of 14wt%, pinch into pills, and vacuum dry at 68°C to a water content of 4.27wt% to obtain the concentrated active heart pills.

[0032] Pill 10: Step 1: weigh the following raw materials by mass: 30 parts of Ganoderma lucidum, 0.4 parts of artificial musk, 1 part of bear gall, 0.35 parts of bezoar, 0.3 parts of pearl, 25 parts of ginseng, 4 parts of toad venom, 12 parts of aconite root, 0.4 parts of borneol, 5 parts of safflower and 5 parts of starch; Step 2: Ganoderma lucidum, ginseng, toad venom, aconite root and safflower are crushed to obtain powder, and water 32 times the weight of the powder is added, and the mixture is boiled and kept at 78°C and stirred at 60 rpm for 4.5 hours to obtain an intermediate product 1; Step 3: add 300u / g of ficin and 400u / g of ginger to the intermediate product 1, perform enzymolysis at 55°C and stir at 60rpm for 3.8 hours, then inactivate the enzyme to obtain the intermediate product 2; Step 4: sterilize the intermediate product 2, add 3.2% of the carbon source glucose, 0.05% of the nitrogen source potassium dihydrogen phosphate and fermentation bacteria compared to the mass of the intermediate product 2, control the fermentation temperature to 37°C and stir at 60 rpm for 170 hours, then sterilize and filter to obtain the intermediate product 3 filtrate; The fermentation bacteria are Lactobacillus paracasei CICC 6235 and Bacillus subtilis CICC 10262 in a ratio of 1:5. The total inoculation number of live fermentation bacteria in the intermediate product 2 is 2.70×10 10 cfu / g; Step 5: Add artificial musk, bear bile, bezoar, pearl, borneol and starch to the intermediate product three, stir at 80rpm for 0.5 hour, then concentrate under reduced pressure at 55°C to a water content of 14wt%, pinch into pills, and vacuum dry at 68°C to a water content of 4.27wt% to obtain the concentrated active heart pills.

[0033] Huoxin Pills Effect Test: Modeling experiment: A number of SPF-grade SD male rats weighing 200±20g (Chengdu Enswell Biotechnology Co., Ltd.) were selected, and all rats were adaptively fed with ordinary feed for 5 days; then some rats were fed with high-fat feed (45% fat energy high-fat feed, Jiangsu Collaborative Pharmaceutical Bioengineering Co., Ltd.) for 6 consecutive weeks for modeling treatment, and some rats were fed with ordinary feed for 6 weeks; the rats with successful modeling were randomly divided into model control group, positive drug group, pill 1-10 group according to body weight, a total of 13 groups, with 10 rats in each group, and 10 rats were randomly selected from the rats fed with ordinary feed as blank group rats.

[0034] Before conducting the drug administration experiment, the drug solutions were prepared: positive drug group drug solution: simvastatin tablets (Hangzhou Merck Pharmaceuticals Co., Ltd.) were diluted with normal saline to obtain a simvastatin active concentration of 0.4 mg / mL, which was used as the positive drug group drug solution; pill 1-10 group drug solution: the above pills 1-10 were diluted with normal saline to a concentration of 1.3 mg pill / mL, respectively, as the drug solution.

[0035] Drug administration experiment: The rats in the positive drug group and pill 1-10 group were gavaged with 1 mL of drug solution / 100 g of rat once a day, while the rats in the model group and blank group were gavaged with an equal amount of normal saline in the same way; and during the drug administration period, the positive drug group, pill 1-10 group, and model group continued to be fed with high-fat feed, and the blank group continued to be fed with ordinary feed; the drug administration experiment lasted for 2 consecutive months.

[0036] 12 hours after the last administration, the rats were anesthetized, blood was collected from the abdominal artery, and serum was separated. The contents of TC, TG, LDL-C, and HDL-C were tested according to the instructions of the kit. The data were statistically analyzed using SPSS26.0 software, and one-way analysis of variance was used for comparison between multiple groups. The data of each group were compared with the model control group, and P was less than 0.05, which was statistically significant. The test results of each group are shown in Table 1.

[0037] Table 1: TC, TG, LDL-C and HDL-C content test TC / mmol / L TG / mmol / L LDL-C / mmol / L HDL-C / mmol / L Blank Group 2.536±0.217 1.125±0.103 0.863±0.095 1.651±0.184 Model Group 4.395±0.453 2.702±0.298 2.094±0.253 0.896±0.079 Positive drug group 2.948±0.241 1.364±0.142 1.152±0.127 1.467±0.153 Pill 1 group 2.993±0.305 1.429±0.163 1.176±0.114 1.375±0.141 Pill 2 group 3.012±0.229 1.442±0.171 1.185±0.205 1.369±0.158 Pills 3 groups 3.281±0.374 1.635±0.209 1.324±0.197 1.297±0.105 Pills 4 groups 3.097±0.427 1.501±0.114 1.229±0.106 1.346±0.167 Pill 5 group 3.125±0.198 1.523±0.195 1.245±0.122 1.338±0.144 Pills 6 groups 3.672±0.336 1.916±0.247 1.526±0.169 1.192±0.109 Pill 7 group 3.256±0.295 1.617±0.190 1.312±0.110 1.304±0.136 Pills 8 groups 3.289±0.392 1.640±0.227 1.328±0.154 1.295±0.118 Pills 9 Group 3.084±0.203 1.494±0.134 1.223±0.135 1.350±0.152 Pills 10 sets 3.153±0.260 1.543±0.125 1.257±0.101 1.332±0.128 The data in Table 1 were converted to calculate the average values ​​of each group compared with the model group, and the decrease degree △ value of TC, TG, LDL-C and the increase degree △ value of HDL-C content were calculated. The results are shown in Table 2.

[0038] Table 2: Changes in TC, TG, LDL-C and HDL-C levels compared with the model group test △TC / mmol / L △TG / mmol / L △LDL-C / mmol / L △HDL-C / mmol / L Blank Group 1.859 1.577 1.231 0.755 Positive drug group 1.447 1.338 0.942 0.571 Pill 1 group 1.402 1.273 0.918 0.479 Pill 2 group 1.383 1.260 0.909 0.473 Pills 3 groups 1.114 1.067 0.770 0.401 Pills 4 groups 1.298 1.201 0.865 0.450 Pill 5 group 1.270 1.179 0.849 0.442 Pill 6 group 0.723 0.786 0.568 0.296 Pill 7 group 1.139 1.085 0.782 0.408 Pills 8 groups 1.106 1.062 0.766 0.399 Pills 9 Group 1.311 1.208 0.871 0.454 Pills 10 sets 1.242 1.159 0.837 0.436 In the above table, TC is serum total cholesterol, which refers to the sum of cholesterol contained in all lipoproteins in the blood and is used as an indicator of lipid metabolism. TG is triglyceride, and elevated triglyceride may cause hyperlipidemia. HDL-C is high-density lipoprotein, a lipoprotein that can transport cholesterol to the liver for metabolism, and mainly acts against atherosclerosis. LDL-C is low-density lipoprotein cholesterol, which easily invades blood vessels and deposits in the intima, thereby forming plaques.

[0039] According to the test results in Table 1-2, the concentrated active pills prepared by the present invention have excellent lipid-lowering effects, can significantly reduce the levels of TC, TG and LDL-C in serum and effectively increase the HDL-C content.

[0040] According to the test results of pill groups 1, 3 and 6 in the table, the enzymatic hydrolysis and fermentation processes adopted in the present invention can effectively improve the efficacy of the pills and increase their lipid-lowering effect.

[0041] According to the test results of pill groups 1, 4-5 in the table, the present invention uses a combination of ficin and ginger protease during enzymatic hydrolysis, which can produce a compound effect, effectively reduce the TC, TG and LDL-C levels in serum and increase the HDL-C content, giving the active pills excellent lipid-lowering effect.

[0042] According to the test results of Table 1, 7-10, the present invention uses Lactobacillus paracasei CICC6235 and Bacillus subtilis CICC 10262 for joint fermentation in the fermentation process, and the two have a synergistic effect in promoting the effect of lowering blood lipids. The joint fermentation of the two can significantly reduce TC, TG and LDL-C content and increase HDL-C content. In addition, during the fermentation process, when the live bacteria of Lactobacillus paracasei CICC 6235 and Bacillus subtilis CICC 10262 are selected in a quantity ratio of 1:1.2-2.5, the prepared active pills have a better effect.

[0043] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A method for preparing concentrated heart-activating pills, characterized in that: The following steps are involved: Step 1: weigh the raw materials according to mass: ganoderma lucidum, artificial musk, bear gall, bezoar, pearl, ginseng, toad venom, aconite root, borneol, safflower and starch; Step 2: Ganoderma lucidum, ginseng, toad venom, aconite root and safflower are crushed to obtain powder, and water is added to boil and then stirred to obtain intermediate product 1; Step 3: adding ficin and ginger protease to the intermediate product 1 to inactivate the enzymes to obtain the intermediate product 2; Step 4: sterilize the intermediate product II, add a carbon source, a nitrogen source and fermentation bacteria, ferment, sterilize, filter, and obtain an intermediate product III filtrate; Step 5: Add artificial musk, bear bile, bezoar, pearl, borneol and starch to the intermediate product three, stir, concentrate under reduced pressure, make pills, and dry to obtain the concentrated heart-activating pills.

2. The preparation method according to claim 1, characterized in that: In step 1, the raw materials are weighed according to mass parts: 20-40 parts of Ganoderma lucidum, 0.2-0.5 parts of artificial musk, 0.5-2 parts of bear bile, 0.2-0.5 parts of bezoar, 0.2-0.4 parts of pearl, 20-30 parts of ginseng, 2-5 parts of toad venom, 8-15 parts of aconite, 0.2-0.5 parts of borneol, 2-6 parts of safflower and 3-6 parts of starch.

3. The preparation method according to claim 1, characterized in that: In step 2, the mass ratio of powder to water is 1:15-40; the heat preservation and stirring conditions are: heat preservation and stirring at 70-82° C. for 2-6 hours.

4. The preparation method according to claim 1, characterized in that: In step 3, the amounts of ficin and ginger protease added to the intermediate product 1 are 220-400u / g and 250-500u / g respectively; the enzymatic hydrolysis conditions are: enzymatic hydrolysis at 40-60°C and stirring for 2-5 hours.

5. The preparation method according to claim 1, characterized in that: In step 4, the carbon source includes glucose, which is added to product two in an amount of 1-4wt%; the nitrogen source includes potassium dihydrogen phosphate, which is added to product two in an amount of 0.02-0.065wt%.

6. The preparation method according to claim 1, characterized in that: In step 4, the fermentation bacteria are composed of live bacteria of Lactobacillus paracasei CICC 6235 and Bacillus subtilis CICC 10262 in a ratio of 1:1.2-2.5, and the total inoculation number of live bacteria of the fermentation bacteria in the intermediate product 2 is 1.1×10 10 -3.7×10 10 cfu / g.

7. The preparation method according to claim 1, characterized in that: In step 4, the fermentation condition is 30-38° C. with stirring for 100-200 hours.

8. The preparation method according to claim 1, characterized in that: In step 5, the mixture is concentrated under reduced pressure to a water content of 10-15 wt%.

9. The preparation method according to claim 1, characterized in that: In step 5, the drying temperature is 50-70°C.

10. Concentrated heart-activating pills prepared by the preparation method according to any one of claims 1 to 9.